Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Leases: 2019-2025

Historic Current Leases for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $4.1 million.

  • Arcturus Therapeutics Holdings' Current Leases rose 20.00% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 20.00%. This contributed to the annual value of $3.6 million for FY2024, which is 17.57% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Current Leases stood at $4.1 million for Q3 2025, which was up 2.26% from $4.0 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Current Leases high stood at $4.3 million for Q4 2023, and its period low was $1.4 million during Q2 2021.
  • For the 3-year period, Arcturus Therapeutics Holdings' Current Leases averaged around $4.0 million, with its median value being $4.0 million (2025).
  • Its Current Leases has fluctuated over the past 5 years, first soared by 155.09% in 2022, then fell by 18.21% in 2024.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Current Leases stood at $1.5 million in 2021, then soared by 152.70% to $3.9 million in 2022, then grew by 10.94% to $4.3 million in 2023, then dropped by 17.57% to $3.6 million in 2024, then increased by 20.00% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $4.0 million for Q2 2025, and $3.7 million during Q1 2025.